Fresenius SE KGaA Past Earnings Performance
Past criteria checks 0/6
Fresenius SE KGaA's earnings have been declining at an average annual rate of -25.1%, while the Healthcare industry saw earnings growing at 10.1% annually. Revenues have been declining at an average rate of 13.1% per year.
Key information
-25.1%
Earnings growth rate
-25.3%
EPS growth rate
| Healthcare Industry Growth | 13.4% |
| Revenue growth rate | -13.1% |
| Return on equity | 1.8% |
| Net Margin | -2.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Fresenius SE KGaA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 22,811 | -479 | 3,178 | 615 |
| 30 Jun 24 | 22,632 | 721 | 3,203 | 615 |
| 31 Mar 24 | 22,417 | 420 | 3,173 | 604 |
| 31 Dec 23 | 22,299 | 353 | 3,155 | 608 |
| 30 Sep 23 | 21,361 | 1,810 | 3,183 | 647 |
| 30 Jun 23 | 21,560 | 555 | 3,238 | 625 |
| 31 Mar 23 | 17,071 | 952 | 2,365 | 578 |
| 31 Dec 22 | 21,532 | 1,154 | 3,094 | 614 |
| 30 Sep 22 | 25,828 | 1,444 | 3,561 | 610 |
| 30 Jun 22 | 29,766 | 1,611 | 4,080 | 677 |
| 31 Mar 22 | 38,256 | 1,796 | 5,580 | 777 |
| 31 Dec 21 | 37,520 | 1,818 | 5,453 | 784 |
| 30 Sep 21 | 36,858 | 1,729 | 5,423 | 800 |
| 30 Jun 21 | 36,452 | 1,743 | 5,341 | 757 |
| 31 Mar 21 | 36,126 | 1,683 | 5,149 | 758 |
| 31 Dec 20 | 36,277 | 1,707 | 5,235 | 758 |
| 30 Sep 20 | 36,284 | 1,812 | 5,378 | 741 |
| 30 Jun 20 | 36,208 | 1,829 | 5,418 | 752 |
| 31 Mar 20 | 36,049 | 1,889 | 5,517 | 698 |
| 31 Dec 19 | 35,409 | 1,883 | 5,406 | 660 |
| 30 Sep 19 | 34,933 | 1,884 | 5,159 | 644 |
| 30 Jun 19 | 34,283 | 1,859 | 5,105 | 613 |
| 31 Mar 19 | 33,904 | 2,040 | 4,991 | 635 |
| 31 Dec 18 | 33,530 | 2,027 | 4,893 | 646 |
| 30 Sep 18 | 33,390 | 2,022 | 5,136 | 660 |
| 30 Jun 18 | 33,495 | 1,999 | 5,177 | 640 |
| 31 Mar 18 | 33,645 | 1,797 | 5,341 | 596 |
| 31 Dec 17 | 33,886 | 1,814 | 5,554 | 558 |
| 30 Sep 17 | 33,011 | 1,745 | 5,192 | 524 |
| 30 Jun 17 | 32,147 | 1,731 | 5,143 | 513 |
| 31 Mar 17 | 30,818 | 1,659 | 4,933 | 508 |
| 31 Dec 16 | 29,471 | 1,560 | 4,742 | 502 |
| 30 Sep 16 | 28,908 | 1,477 | 4,620 | 480 |
| 30 Jun 16 | 28,415 | 1,452 | 4,489 | 473 |
| 31 Mar 16 | 28,158 | 1,399 | 4,413 | 473 |
| 31 Dec 15 | 27,626 | 1,358 | 4,195 | 464 |
| 30 Sep 15 | 26,889 | 1,256 | 4,031 | 443 |
| 30 Jun 15 | 25,927 | 1,175 | 3,832 | 422 |
| 31 Mar 15 | 24,502 | 1,136 | 3,533 | 394 |
| 31 Dec 14 | 23,231 | 1,067 | 3,359 | 369 |
| 30 Sep 14 | 22,010 | 1,094 | 3,170 | 359 |
| 30 Jun 14 | 21,077 | 1,083 | 3,057 | 351 |
| 31 Mar 14 | 20,653 | 1,040 | 3,055 | 352 |
| 31 Dec 13 | 20,331 | 1,011 | 3,044 | 348 |
Quality Earnings: FRE is currently unprofitable.
Growing Profit Margin: FRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FRE is unprofitable, and losses have increased over the past 5 years at a rate of 25.1% per year.
Accelerating Growth: Unable to compare FRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FRE is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (15.2%).
Return on Equity
High ROE: FRE has a negative Return on Equity (1.85%), as it is currently unprofitable.